LL 37 Interactions: Alcohol, Caffeine, Food & Other Compounds

LL-37 is the only human cathelicidin-derived antimicrobial peptide, a 37-residue amphipathic fragment released from the hCAP18 precursor. Because it is an endogenous host-defence molecule rather than an oral supplement, the "interaction" questions people ask about it — alcohol, caffeine, food, fasting, stacking with other compounds — map poorly onto how it has actually been studied. This page separates two categories: interactions that published studies measured, and questions where no interaction study exists, in which case the reasoning researchers apply is described and explicitly labelled as mechanistic inference.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes a protocol, a combination, or a timing strategy.

What "interaction" Means in the LL-37 Literature

In pharmacology, an interaction usually means one substance changing another's absorption, metabolism or clearance. Almost none of the LL-37 literature is built that way. Instead, the field has characterised molecular binding partners and signalling context — what LL-37 attaches to, what it neutralises, and which host pathways change when it is present.

A representative example: researchers reported that LL-37 interacted with ApoB-100 and that this cathelicidin–ApoB-100 interaction promoted LDL clearance while attenuating cholesterol accumulation in the liver (PMID 40971038). That is an interaction in the biochemical sense — a peptide binding a lipoprotein — not a drug–drug interaction in the clinical sense. Readers searching for "LL-37 interactions" will find that the published record is overwhelmingly of the first type.

LL-37 and Alcohol: No Interaction Study Identified

No study in the verified literature examined LL-37 alongside ethanol, alcoholic beverages, or alcohol-induced changes in peptide behaviour. There is no reported measurement of how alcohol affects circulating cathelicidin, how it changes LL-37's membrane activity, or whether co-exposure alters any outcome.

Mechanistic reasoning (labelled as reasoning, not evidence): investigators who study LL-37 emphasise that its core activity is membrane-directed. Work on antimicrobial peptide–membrane behaviour characterised how LL-37 and related peptides interacted with lipid bilayers when delivered from microgel carriers (PMID 31855795). Because ethanol is itself a membrane-perturbing solvent, a researcher would predict that bilayer fluidity is a variable worth controlling in such experiments. That prediction has not been tested in the cited work and should not be read as a finding.

Why liver context appears in searches

The hepatic angle in the LL-37 literature comes from lipoprotein handling rather than from alcohol. The ApoB-100 study reported effects on LDL clearance and hepatic cholesterol accumulation (PMID 40971038); it did not involve alcohol exposure, and no inference about drinking can be drawn from it.

LL-37 and Caffeine: No Interaction Study Identified

No verified paper tested caffeine, coffee, tea or other methylxanthines with LL-37. There is no reported dose, no reported effect, and no reported adverse event for that pairing anywhere in this citation set.

Mechanistic reasoning (labelled as reasoning): one avenue investigators might flag is calcium signalling. A 2025 study reported that LL-37 increased rhinovirus-induced interferon-β expression in human airway epithelial cells through a Ca²⁺-dependent mechanism (PMID 40612001). Caffeine is known in general pharmacology to influence intracellular calcium handling, so a reviewer could reasonably nominate calcium flux as a hypothetical point of overlap. No experiment in the cited literature combined the two, and the hypothesis carries no evidential weight on its own.

LL-37, Food and Fasting: What Is and Is Not Documented

No study in this set examined meal timing, fasted versus fed states, macronutrient composition, or caloric restriction in relation to LL-37. Because LL-37 is a peptide produced by epithelial cells, neutrophils and monocytes rather than an ingested compound with an absorption window, the "take with food or on an empty stomach" framing has no analogue in the published work.

Two dietary-adjacent findings do exist and are frequently conflated with food-timing questions:

• Vitamin D. A 2025 study described LL-37 as a vitamin D-inducible antimicrobial peptide and reported that it bound SARS-CoV-2 Spike and the accessory proteins ORF7a and ORF8 (PMID 41064641). The vitamin D relationship there is descriptive of how cathelicidin expression is regulated; the study's experimental finding concerned protein binding, not supplementation outcomes.
• Lactoferrin. A 2022 study reported that the host defence peptides LL-37 and lactoferrin triggered extracellular trap release from blood-derived circulating monocytes (PMID 35203676). Lactoferrin is a milk- and secretion-derived protein, which is why it surfaces in dietary searches, but the work described was cell-based immunology rather than nutrition.

Lipids as the closest dietary link

The most direct nutrition-adjacent mechanism reported is lipoprotein binding: researchers described LL-37's interaction with ApoB-100 promoting LDL clearance and reducing cholesterol accumulation in the liver (PMID 40971038). This is a lipid-biology finding, not a dietary recommendation, and the study did not report human dietary interventions.

Compound and Co-Factor Interactions That Studies Did Examine

The table below summarises interactions that are actually documented in the verified citation set. Each row reflects what the cited paper reported, nothing broader.

Immune signalling: the most studied "interaction" of all

A 2020 review in Frontiers in Immunology covered how cathelicidins modulated TLR activation and inflammation (PMID 32582207). This matters for interaction questions because TLR pathways are where LL-37 meets microbial ligands, endogenous nucleic acids and inflammatory stimuli — the practical crossroads at which the peptide's behaviour changes depending on what else is present in the environment.

Neutrophil and monocyte extracellular traps

A 2022 review described LL-37 as a multi-faceted amphipathic peptide involved in NETosis (PMID 35954305), and a separate 2022 study reported that LL-37 together with lactoferrin triggered extracellular trap release from blood-derived circulating monocytes (PMID 35203676). Not every trap contains the peptide: a 2025 study reported that Legionella pneumophila-induced NETs did not bear LL-37 peptides (PMID 41156758), which illustrates how strongly context determines whether LL-37 is part of a given response.

Microbial counter-interactions

Interactions run both ways. A 2026 Nature Microbiology study reported that the pneumococcal S protein coordinated cell wall modification and repair to resist host antimicrobials (PMID 41420059). In other words, bacterial machinery can blunt cathelicidin activity — an interaction category distinct from anything a reader can consume.

Delivery Systems and Formulation Interactions

Where LL-37 has been combined with something deliberately in the laboratory, it is usually a material rather than a drug. Researchers characterised membrane interactions of antimicrobial peptide-loaded microgels (PMID 31855795), and a separate group investigated nanoclay-induced bacterial flocculation as a strategy for infection confinement (PMID 31837621). These are formulation-science studies: they describe how a carrier changes where a peptide goes and what it contacts, not how a peptide behaves alongside a beverage or supplement.

Neurological Context: What Studies Report

Two papers place cathelicidin in central-nervous-system settings. A 2022 Molecular Psychiatry study reported that human antimicrobial peptide LL-37 contributed to Alzheimer's disease progression (PMID 36138130). A 2022 Glia study reported that cathelicidin-related antimicrobial peptide promoted neuroinflammation through astrocyte–microglia communication in experimental autoimmune encephalomyelitis (PMID 35670184). These findings are relevant to interaction questions only in that they show the peptide's effects are context-dependent and not uniformly beneficial; neither study involved alcohol, caffeine, food or any consumer compound.

How to Read the Absence of Interaction Data

Absence of a study is not the same as absence of an effect, and it is equally not evidence of an effect. In the verified literature reviewed here, the following statements are accurate:

1. No study tested LL-37 with alcohol.
2. No study tested LL-37 with caffeine.
3. No study tested LL-37 under fasted versus fed conditions or with specific meals.
4. No study reported dosing schedules for LL-37 in combination with any consumer compound.
5. The documented interactions are molecular and cellular — lipoproteins (PMID 40971038), TLR pathways (PMID 32582207), viral proteins (PMID 41064641), other host peptides (PMID 35203676) and delivery materials (PMID 31855795).

Anyone encountering confident claims about combining LL-37 with a stimulant, a drink or a meal pattern should note that no cited study in this set supports such a claim, and that mechanistic plausibility is a hypothesis-generating tool rather than a result.

Regulatory Status Note

LL-37 is not an approved drug product. Synthetic cathelicidin peptides supplied for laboratory work carry research-use-only designations, and research-use-only material is not authorised for human administration. This paragraph states regulatory facts and is not legal advice.

References

• Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver (Science China Life Sciences, 2026)
• Cathelicidins Modulate TLR-Activation and Inflammation (Frontiers in Immunology, 2020)
• Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8 (Frontiers in Cellular and Infection Microbiology, 2025)
• Host Defense Peptides LL-37 and Lactoferrin Trigger ET Release from Blood-Derived Circulating Monocytes (Biomedicines, 2022)
• Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism (Biochemistry and Biophysics Reports, 2025)
• LL-37, a Multi-Faceted Amphipathic Peptide Involved in NETosis (Cells, 2022)
• Legionella pneumophila-Induced NETs Do Not Bear LL-37 Peptides (Microorganisms, 2025)
• Pneumococcal S protein coordinates cell wall modification and repair to resist host antimicrobials (Nature Microbiology, 2026)
• Membrane interactions of antimicrobial peptide-loaded microgels (Journal of Colloid and Interface Science, 2020)
• Nanoclay-induced bacterial flocculation for infection confinement (Journal of Colloid and Interface Science, 2020)
• Human antimicrobial peptide LL-37 contributes to Alzheimer's disease progression (Molecular Psychiatry, 2022)
• Cathelicidin-related antimicrobial peptide promotes neuroinflammation through astrocyte-microglia communication in experimental autoimmune encephalomyelitis (Glia, 2022)